Andrew D Goodman1, Theodore R Brown1, Randall T Schapiro1, Michael Klingler1, Ron Cohen1, Andrew R Blight1. 1. Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA (ADG); Evergreen Hospital Medical Center, Kirkland, WA, USA (TRB); Minneapolis Clinic of Neurology, Minneapolis, MN, USA (RTS); and Acorda Therapeutics, Inc., Ardsley, NY, USA (MK, RC, ARB).
Abstract
BACKGROUND: Two phase 3 clinical trials demonstrated that dalfampridine extended-release 10-mg tablets (D-ER), twice daily, significantly improved walking relative to placebo in patients with multiple sclerosis (MS). The objective of this study was to evaluate the efficacy and safety of D-ER in patients with MS using pooled data from the two phase 3 trials. METHODS: Data were pooled from the two trials, and D-ER was compared with placebo for timed-walk responder rate, changes in walking speed, and the 12-item Multiple Sclerosis Walking Scale (MSWS-12). Response rates were evaluated with respect to demographic and clinical characteristics. RESULTS:D-ER had a significantly higher proportion of timed-walk responders relative to placebo (37.6% vs. 8.9%; P < .0001). The responder rate was independent of age, gender, race, body-mass index, type of MS, duration of MS, baseline Expanded Disability Status Scale score, baseline walking speed, and concomitant use of immunomodulatory therapies. Significant improvements were observed in walking speed and in MSWS-12 score for the pooled D-ER group compared with placebo. The safety profile was consistent with the individual studies; no new safety or tolerability concerns were identified. CONCLUSIONS:D-ER demonstrated efficacy for the improvement of walking in patients with MS; response was independent of demographic and clinical characteristics.
RCT Entities:
BACKGROUND: Two phase 3 clinical trials demonstrated that dalfampridine extended-release 10-mg tablets (D-ER), twice daily, significantly improved walking relative to placebo in patients with multiple sclerosis (MS). The objective of this study was to evaluate the efficacy and safety of D-ER in patients with MS using pooled data from the two phase 3 trials. METHODS: Data were pooled from the two trials, and D-ER was compared with placebo for timed-walk responder rate, changes in walking speed, and the 12-item Multiple Sclerosis Walking Scale (MSWS-12). Response rates were evaluated with respect to demographic and clinical characteristics. RESULTS: D-ER had a significantly higher proportion of timed-walk responders relative to placebo (37.6% vs. 8.9%; P < .0001). The responder rate was independent of age, gender, race, body-mass index, type of MS, duration of MS, baseline Expanded Disability Status Scale score, baseline walking speed, and concomitant use of immunomodulatory therapies. Significant improvements were observed in walking speed and in MSWS-12 score for the pooled D-ER group compared with placebo. The safety profile was consistent with the individual studies; no new safety or tolerability concerns were identified. CONCLUSIONS: D-ER demonstrated efficacy for the improvement of walking in patients with MS; response was independent of demographic and clinical characteristics.
Authors: Andrew D Goodman; Theodore R Brown; Keith R Edwards; Lauren B Krupp; Randall T Schapiro; Ron Cohen; Lawrence N Marinucci; Andrew R Blight Journal: Ann Neurol Date: 2010-10 Impact factor: 10.422
Authors: João Carlos Correia de Sa; Laura Airas; Emmanuel Bartholome; Nikolaos Grigoriadis; Heinrich Mattle; Celia Oreja-Guevara; Jonathan O'Riordan; Finn Sellebjerg; Bruno Stankoff; Karl Vass; Agata Walczak; Heinz Wiendl; Bernd C Kieseier Journal: Ther Adv Neurol Disord Date: 2011-05 Impact factor: 6.570
Authors: Katherine Treadaway; Gary Cutter; Amber Salter; Sharon Lynch; James Simsarian; John Corboy; Douglas Jeffery; Bruce Cohen; Ken Mankowski; Joseph Guarnaccia; Lawrence Schaeffer; Roy Kanter; David Brandes; Charles Kaufman; David Duncan; Ellen Marder; Arthur Allen; John Harney; Joanna Cooper; Douglas Woo; Olaf Stüve; Michael Racke; Elliot M Frohman Journal: J Neurol Date: 2009-04-27 Impact factor: 4.849
Authors: Ka-Hoo Lam; Caspar E P van Munster; Marcus D'Souza; Saskia Steinheimer; Christian P Kamm; Jessica Burggraaff; Matthew Johnson; Yordan Zaykov; Jonas Dorn; Frank Dahlke; Ludwig Kappos; Joep Killestein; Bernard Uitdehaag Journal: Int J MS Care Date: 2022-06-20
Authors: María Belén Marzal-Alfaro; María Luisa Martín Barbero; JoseM García Domínguez; Fernando Romero-Delgado; María Luisa Martínez Ginés; Ana Herranz; María Sanjurjo-Sáez Journal: Eur J Hosp Pharm Date: 2017-01-13
Authors: Andrew D Goodman; Francois Bethoux; Theodore R Brown; Randall T Schapiro; Ron Cohen; Lawrence N Marinucci; Herbert R Henney; Andrew R Blight Journal: Mult Scler Date: 2015-01-12 Impact factor: 6.312
Authors: Prudence Plummer; Corinne J Bohling; L Ellese Nickles; Alexis A Williams; Amy Thomas; Silva Markovic-Plese; Barbara Giesser Journal: Int J MS Care Date: 2018 Sep-Oct